Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.

Abstract	Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and/or III study results, will be discussed, as well as the most recent safety data.
Authors	Ritu Saini, William D Tutrone, Jeffrey M Weinberg
Journal	Current pharmaceutical design (Curr Pharm Des) Vol. 11 Issue 2 Pg. 273-80 ( 2005) ISSN: 1381-6128 [Print] United Arab Emirates
PMID	15638763 (Publication Type: Journal Article, Review)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Immunoglobulin G Nicotinic Acids Receptors, Tumor Necrosis Factor Recombinant Fusion Proteins pimecrolimus tazarotene Infliximab Alefacept Adalimumab Etanercept Tacrolimus efalizumab
Topics	Adalimumab Administration, Oral Alefacept Animals Antibodies, Monoclonal (pharmacology, therapeutic use) Antibodies, Monoclonal, Humanized Etanercept Humans Immunoglobulin G (pharmacology, therapeutic use) Infliximab Meta-Analysis as Topic Nicotinic Acids (administration & dosage, pharmacokinetics, therapeutic use) Psoriasis (drug therapy, epidemiology, immunology) Receptors, Tumor Necrosis Factor (therapeutic use) Recombinant Fusion Proteins (pharmacology, therapeutic use) Tacrolimus (administration & dosage, analogs & derivatives, pharmacokinetics, therapeutic use) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!